CN110305837A - 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 - Google Patents
磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 Download PDFInfo
- Publication number
- CN110305837A CN110305837A CN201910486821.3A CN201910486821A CN110305837A CN 110305837 A CN110305837 A CN 110305837A CN 201910486821 A CN201910486821 A CN 201910486821A CN 110305837 A CN110305837 A CN 110305837A
- Authority
- CN
- China
- Prior art keywords
- oocyte maturation
- phosphodiesterase
- zebra fish
- maturation
- induction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035800 maturation Effects 0.000 title claims abstract description 52
- 210000000287 oocyte Anatomy 0.000 title claims abstract description 43
- 241000252212 Danio rerio Species 0.000 title claims abstract description 25
- 230000000694 effects Effects 0.000 title claims abstract description 20
- 230000006698 induction Effects 0.000 title claims abstract description 19
- 239000003112 inhibitor Substances 0.000 title claims abstract description 19
- 102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title claims abstract description 17
- 108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title claims abstract description 17
- 229960002639 sildenafil citrate Drugs 0.000 claims abstract description 19
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 claims abstract description 19
- 229960000307 avanafil Drugs 0.000 claims abstract description 17
- WEAJZXNPAWBCOA-INIZCTEOSA-N avanafil Chemical compound C1=C(Cl)C(OC)=CC=C1CNC1=NC(N2[C@@H](CCC2)CO)=NC=C1C(=O)NCC1=NC=CC=N1 WEAJZXNPAWBCOA-INIZCTEOSA-N 0.000 claims abstract description 17
- 229960000835 tadalafil Drugs 0.000 claims abstract description 17
- IEHKWSGCTWLXFU-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C([C]4C=CC=CC4=N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 IEHKWSGCTWLXFU-IIBYNOLFSA-N 0.000 claims abstract description 17
- 241000251468 Actinopterygii Species 0.000 abstract description 10
- 238000002474 experimental method Methods 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000001419 dependent effect Effects 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 210000000130 stem cell Anatomy 0.000 description 20
- 210000004681 ovum Anatomy 0.000 description 12
- 108010000912 Egg Proteins Proteins 0.000 description 11
- 102000002322 Egg Proteins Human genes 0.000 description 11
- 238000000034 method Methods 0.000 description 8
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 6
- 230000001568 sexual effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 238000012545 processing Methods 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 4
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 230000021121 meiosis Effects 0.000 description 4
- 229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 101001098818 Homo sapiens cGMP-inhibited 3',5'-cyclic phosphodiesterase A Proteins 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 102100037093 cGMP-inhibited 3',5'-cyclic phosphodiesterase A Human genes 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101001098806 Dictyostelium discoideum cGMP-specific 3',5'-cGMP phosphodiesterase 3 Proteins 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 241000283070 Equus zebra Species 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011748 cell maturation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 150000002338 glycosides Chemical group 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 108010052522 livetin Proteins 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000000633 nuclear envelope Anatomy 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000004508 polar body Anatomy 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000005070 ripening Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 229960003310 sildenafil Drugs 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229960002381 vardenafil Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0608—Germ cells
- C12N5/0609—Oocytes, oogonia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
Abstract
本发明提供一种磷酸二酯酶5活性抑制剂的一种新用途——即作为诱导斑马鱼***成熟的催熟剂,属于水产技术领域。磷酸二酯酶5活性的抑制剂,包括Sildenafil Citrate、Tadalafil和Avanafil。实验表明,Sildenafil Citrate、Tadalafil和Avanafil在促进***成熟中均表现出计量依赖性、时间依赖性和时期依赖性,而且在斑马鱼中诱导***成熟的效率较高。另外,磷酸二酯酶5活性的抑制剂不仅可用于斑马鱼***成熟的诱导,也可能应用于其他鱼类的***成熟诱导,因此具备良好的应用前景。
Description
技术领域
本发明涉及一种磷酸二酯酶5活性抑制剂的一种新用途——即作为诱导斑马鱼***成熟剂,属于水产技术领域。
背景技术
磷酸二酯酶(PDEs)具有水解细胞内第二信使(cAMP,环磷酸腺苷或cGMP,环磷酸鸟苷)的功能,降解细胞内cAMP或cGMP,从而终结这些第二信使所传导的生化作用。其中磷酸二酯酶5是一种特异性水解cGMP的磷酸二酯酶,其抑制剂有Sildenafil、Vardenafil、Tadalafil和Avanafil,主要用于治疗治疗性功能障碍。近些年,在哺乳动物中发现PDE5参与哺乳动物***成熟的调控,但在鱼类中没有发现类似的报道。本专利主要揭示磷酸二酯酶5活性抑制剂作为一种催熟剂在诱导斑马鱼***成熟中的应用。
在水产实践中,鱼类***的正常成熟至关重要,是获得优质卵子进行育种繁殖的前提。因此***成熟的机制一直以来都是鱼类生殖生理学研究的热点,开发出新型鱼类***催熟剂对鱼类养殖有着重要的意义。)***的成熟是由多种因子调控的复杂过程,也是调控是生殖的关键环节之一。与其他脊椎动物相似,鱼类的卵子从初级***开始发生减数***,到完全生长期停滞在第一次减数***的前期,直到受到由垂体分泌的LH(促***)的刺激之后,减数***恢复,核膜破裂,第一极体排出,并停滞在第二次减数***的中期,这个过程被称为***的成熟,在这个过程中卵黄蛋白结构发生重构,卵子的颜色由不透明变成透明,故此变化也是判断斑马鱼卵子是否发生成熟的标志。
近年,在哺乳动物中已经证明,cGMP参与***的成熟。在***内,cGMP抑制磷酸二酯酶3即PDE3A,维持***中cAMP的高水平,而cAMP对细胞周期蛋白起作用,阻止减数***的进展。LH关闭滤泡细胞与***之间的通道连接关闭,进一步导致***内cGMP显著下降,这将导致cGMP抑制PDE3A活性的功能下降,降低了***内cAMP的含量,使减数***得以恢复。越来越多的环核苷酸磷酸二酯酶被发现参与哺乳动物***的成熟调控,包括环核苷酸磷酸二酯酶3、特异性水解cAMP的环核苷酸磷酸二酯酶4、7、8和特异性水解cGMP的环核苷酸磷酸二酯酶1、5。
***的成熟是一个复杂的动态过程,通过对***成熟机制的深入了解和掌握,才能更好地利用***成熟的规律为现代胚胎生物工程的发展服务。虽然,已经有实验室在体外成熟-体外受精-体外培养方面取得了成功,但体外成熟的***存在受精率较低,细胞质量较差等问题,所以通过对***成熟机理的进一步研究,体外成熟体系将会更加完善。
发明内容
本发明的目的在于提供一种磷酸二酯酶5活性抑制剂的一种新用途——即作为诱导斑马鱼***催熟剂。
下面通过具体实验来说明磷酸二酯酶5抑制剂在诱导斑马鱼***成熟中的应用效果。
1、材料和药品
Leibovitz's L-15 培养基购自 Gibco公司(美国),磷酸二酯酶5抑制剂采用Sildenafil Citrate、Tadalafil、Avanafil,均购自selleck公司(美国)。
2、卵巢卵泡分离和培养
斑马鱼麻醉致死后,解剖10~15条雌性斑马鱼,取出卵巢放在含有用无菌水稀释的、质量百分含量为60%的Leibovitz's L-15培养基的培养皿中,人工分离完全生长期卵子(FG期;直径约为0.65毫米)。分离过程通常在室温下持续3~5h,28℃下孵育和药物处理。
图1是Sildenafil Citrate对***成熟的影响,其中(A) SildenafilCitrate处理16小时对***成熟率的浓度依赖性关系;(B)为 Sildenafil Citrate(10uM)对***成熟率的时间依赖性关系;(C)Sildenafil Citrate(10uM处理14h)对不同直径大小的***的成熟率的影响。
图2是Tadalafil对***成熟的影响,其中(A)Tadalafil处理16小时对***成熟率的浓度依赖性关系;(B)Tadalafil(10uM)对***成熟率的时间依赖性关系;(C)Tadalafil(10uM处理14h)对不同直径大小的***成熟率的影响。
图3是Avanafil对***成熟的影响,其中(A)Avanafil处理16小时对***成熟率的浓度依赖性关系;(B)Avanafil(1000uM)对***成熟率的时间依赖性关系;(C)Avanafil (1000uM处理14h)对不同直径大小的***成熟率的影响。
在上述测试不同剂量的实验中,Sildenafil Citrate、Tadalafil和Avanafil在促进***成熟中均表现出剂量依赖性,且Sildenafil Citrate和Tadalafil 在10uM的浓度时效果最好,Avanafil在1mM时效果最佳。(图1A,图2 A,图3 A)。
在上述测试不同时间的实验中,Sildenafil Citrate、Tadalafil和Avanafil在促进***成熟中均表现出时间依赖性,在14小时可达到最好的效果(图1B,图2 B,图3B)。
在上述测试不同时期的实验中,Sildenafil Citrate、Tadalafil和Avanafil在促进***成熟中均表现出时期依赖性,可诱导完全生长期的卵子发生成熟(图1 C,图2C,图3 C)。
综上所述,磷酸二酯酶5的抑制剂可诱导完全生长期的卵子发生成熟,并具有明确的剂量、时间和时期依赖性。
本发明通过研究,首次发现磷酸二酯酶5活性的抑制剂可诱导斑马鱼***成熟,表明磷酸二酯酶5活性的抑制剂可作为一种新型的诱导鱼类***成熟的试剂应用于鱼类***催熟中。此外磷酸二酯酶5活性的抑制剂在斑马鱼中诱导***成熟的效率较高,不仅可用于斑马鱼***成熟的诱导,也可能应用于其他鱼类的***成熟诱导,因此具备良好的应用前景。
附图说明
图1是Sildenafil Citrate在***成熟过程中的作用。
图2是Tadalafil在***成熟过程中的作用。
图3是Avanafil在***成熟过程中的作用。
具体实施方式
通过具体实验来说明磷酸二酯酶5抑制剂在诱导斑马鱼***成熟中的应用效果。
实施例1、Sildenafil Citrate在诱导斑马鱼***成熟中的应用
斑马鱼麻醉致死后,解剖10~15条雌性斑马鱼,取出卵巢放在含有用无菌水稀释的,质量百分含量为60%的Leibovitz L-15培养基的培养皿中,人工分离完全生长期卵子(FG期;直径约为0.65毫米)。分离过程通常在室温下持续3~5h,28℃下孵育,并用药物处理。药物Sildenafil Citrate的浓度为10uM,处理时间14小时。与对照组相比,诱导***成熟率升高越1.83倍。对照组的成熟率约为40%,Sildenafil Citrate处理组的***成熟率约为73%。
实施例2、Tadalafil在诱导斑马鱼***成熟中的应用
药物Tadalafil的浓度为10uM,处理时间14小时。其他与实施例1同。(与对照组相比,诱导***成熟率升高越2.3倍。对照组的成熟率约为33%,Sildenafil Citrate处理组的***成熟率约为75%。
实施例3、Avanafil在诱导斑马鱼***成熟中的应用
药物Avanafil的浓度为1mM,处理时间14小时。其他与实施例1同。(与对照组相比,诱导***成熟率升高越1.5倍。对照组的成熟率约为52%,Sildenafil Citrate处理组的***成熟率约为78.5%。
Claims (5)
1.磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用。
2.如权利要求1所述磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用,其特征在于:磷酸二酯酶5活性抑制剂为Sildenafil Citrate、Tadalafil、Avanafil。
3.如权利要求2所述磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用,其特征在于:Tadalafil的浓度为0.1~10uM。
4.如权利要求2所述磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用,其特征在于:Sildenafil Citrate的浓度为1~10uM。
5.如权利要求2所述磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用,其特征在于:Avanafil的浓度为10uM~1000uM。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910486821.3A CN110305837A (zh) | 2019-06-05 | 2019-06-05 | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910486821.3A CN110305837A (zh) | 2019-06-05 | 2019-06-05 | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN110305837A true CN110305837A (zh) | 2019-10-08 |
Family
ID=68075044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910486821.3A Pending CN110305837A (zh) | 2019-06-05 | 2019-06-05 | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110305837A (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020103106A1 (en) * | 2000-08-11 | 2002-08-01 | Stephen Palmer | Methods of inducing ovulation |
CN1802177A (zh) * | 2003-04-01 | 2006-07-12 | 应用研究***Ars股份公司 | 用于不育症中的磷酸二酯酶抑制剂 |
CN102266313A (zh) * | 2011-05-17 | 2011-12-07 | 杭州环特生物科技有限公司 | 建立斑马鱼血栓模型的方法及筛选抗栓/致栓药物的方法 |
CN102316870A (zh) * | 2009-01-17 | 2012-01-11 | 拜耳制药股份公司 | sGC刺激剂或sGC活化剂联合PDE5抑制剂用于治疗***功能障碍 |
CN102482644A (zh) * | 2009-05-14 | 2012-05-30 | 阿德莱德研究和创新私人有限公司 | 用于***的收集及成熟的方法 |
US20150147807A1 (en) * | 2012-03-14 | 2015-05-28 | Children's Medical Center Corporation | High-throughput image-based chemical screening in zebrafish blastomere cell culture |
CN109467555A (zh) * | 2018-06-21 | 2019-03-15 | 广东蓝堡生物科技有限公司 | 一种他达那非衍生物及其制备方法和应用 |
-
2019
- 2019-06-05 CN CN201910486821.3A patent/CN110305837A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020103106A1 (en) * | 2000-08-11 | 2002-08-01 | Stephen Palmer | Methods of inducing ovulation |
CN1802177A (zh) * | 2003-04-01 | 2006-07-12 | 应用研究***Ars股份公司 | 用于不育症中的磷酸二酯酶抑制剂 |
CN102316870A (zh) * | 2009-01-17 | 2012-01-11 | 拜耳制药股份公司 | sGC刺激剂或sGC活化剂联合PDE5抑制剂用于治疗***功能障碍 |
CN102482644A (zh) * | 2009-05-14 | 2012-05-30 | 阿德莱德研究和创新私人有限公司 | 用于***的收集及成熟的方法 |
CN102266313A (zh) * | 2011-05-17 | 2011-12-07 | 杭州环特生物科技有限公司 | 建立斑马鱼血栓模型的方法及筛选抗栓/致栓药物的方法 |
US20150147807A1 (en) * | 2012-03-14 | 2015-05-28 | Children's Medical Center Corporation | High-throughput image-based chemical screening in zebrafish blastomere cell culture |
CN109467555A (zh) * | 2018-06-21 | 2019-03-15 | 广东蓝堡生物科技有限公司 | 一种他达那非衍生物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Lindner et al. | Intraovarian factors in ovulation: determinants of follicular response to gonadotrophins | |
CN107384854B (zh) | 人类***胞浆成熟优化液 | |
CN103827293A (zh) | 用于增强雌性生殖细胞中生物能状态的组合物和方法 | |
Versieren et al. | Developmental competence of parthenogenetic mouse and human embryos after chemical or electrical activation | |
Rosati | Sperm-egg interaction in ascidians | |
CN101003800A (zh) | 使用来自无血清饥饿的分化细胞的供体细胞核进行克隆 | |
CN110833542A (zh) | 褪黑素在制备用于改善***质量药物中的应用 | |
Tessarollo | Manipulating mouse embryonic stem cells | |
US20190048365A1 (en) | Mitochondrial microinjection of oocytes | |
CN112568326A (zh) | 一种蛋禽用抗应激复合预混合饲料及其制备方法与应用 | |
Rahat et al. | Cultivation of bacteria-free Hydra viridis: missing budding factor in nonsymbiotic hydra | |
CN111956657A (zh) | 一种改善卵巢功能、提高卵子和胚胎质量的组合物及其应用 | |
Rothschild et al. | Maturation and egg-laying of the rabbit flea (Spilopsyllus cuniculi Dale) induced by the external application of hydrocortisone | |
Park et al. | Assisted reproductive techniques and genetic manipulation in the common marmoset | |
Morgan et al. | Latent viral infection of cells in tissue culture: IV. Latent infection of L cells with psittacosis virus | |
SHORB et al. | Requirement of trichomonads for unidentified growth factors, saturated and unsaturated fatty acids | |
CN110305837A (zh) | 磷酸二酯酶5活性抑制剂作为诱导斑马鱼***成熟的催熟剂的应用 | |
CN109182252B (zh) | 一种斑马鱼***催熟剂及其应用 | |
Reddy et al. | Effect of thyroid hormones on hatching in the tilapia, Oreochromis mossambicus | |
Crews | On the origin of sexual behavior | |
CN107460208B (zh) | 哺乳动物体细胞克隆方法和使用的培养液 | |
Biber et al. | Effects of in utero alcohol exposure on B‐cell development in the murine fetal liver | |
CN104694475A (zh) | 一种新型神经干细胞培养添加剂及筛选方法、应用及利用该添加剂的培养基 | |
Chang et al. | Differential effects of gonadotropin and orthovanadate on oocyte maturation, ovulation, and prostaglandin synthesis by Rana ovarian follicles in vitro | |
Ruben et al. | Diabetes produced by feeding alloxan to cats |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20191008 |